Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Takeda Obtains 100% Control of China JV

publication date: Oct 21, 2010
Takeda Pharma of Japan will acquire the remaining 25% of its China JV, Tianjin Takeda Pharmaceuticals Co., Ltd., from its former partner, Tianjin Lisheng Pharma, giving Takeda complete control of the enterprise. Lishing, a state-owned company, decided last year to sell its 25% stake. By law, Lishing was required to hold an auction, and Takeda was the only bidder, though the amount was not disclosed. More details....

Stock Symbol: (TO: 4502)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital